Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huatan Dingji Fang (HTDJ) is a Traditional Chinese Medicine (TCM) herbal formula developed at Longhua Hospital, Shanghai University of Traditional Chinese Medicine, for the treatment of atrial fibrillation (AF). Created by Professor Lin Zhongxiang, the formula is specifically indicated for patients presenting with the TCM syndrome of 'qi deficiency and phlegm opacities' (palpitation of Qi deficiency-caused phlegm stagnation). It is a complex decoction comprising sixteen herbs, including *Pinellia ternata*, *Astragalus membranaceus*, *Coptis chinensis*, and *Sophora flavescens*. HTDJ is thought to exert antiarrhythmic effects through multiple mechanisms, including the modulation of cardiac electrophysiology and providing cardiovascular protection, potentially via active constituents like matrine, artemisinin, and icariin. The formula is currently being investigated in randomized, double-blind clinical trials as an adjunctive therapy to standard Western medicine for AF management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huatan Dingji Fang.